| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 … YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ... The Lancet 376 (9742), 687-697, 2010 | 7881 | 2010 |
| Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12 … YK Kang, N Boku, T Satoh, MH Ryu, Y Chao, K Kato, HC Chung, JS Chen, ... The Lancet 390 (10111), 2461-2471, 2017 | 2084 | 2017 |
| Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial CS Fuchs, T Doi, RW Jang, K Muro, T Satoh, M Machado, W Sun, SI Jalal, ... JAMA oncology 4 (5), e180013-e180013, 2018 | 1645 | 2018 |
| Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ... The Lancet 392 (10142), 123-133, 2018 | 1147 | 2018 |
| Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab K Yonesaka, K Zejnullahu, I Okamoto, T Satoh, F Cappuzzo, J Souglakos, ... Science translational medicine 3 (99), 99ra86-99ra86, 2011 | 701 | 2011 |
| Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study T Satoh, RH Xu, HC Chung, GP Sun, T Doi, JM Xu, A Tsuji, Y Omuro, J Li, ... J Clin Oncol 32 (19), 2039-2049, 2014 | 695 | 2014 |
| Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non–small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial … S Kudoh, K Takeda, K Nakagawa, M Takada, N Katakami, K Matsui, ... Journal of Clinical Oncology 24 (22), 3657-3663, 2006 | 494 | 2006 |
| Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial T Kudo, Y Hamamoto, K Kato, T Ura, T Kojima, T Tsushima, S Hironaka, ... The Lancet Oncology 18 (5), 631-639, 2017 | 383 | 2017 |
| ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction … YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ... Lancet 376 (9742), 687-697, 2010 | 356 | 2010 |
| The epitranscriptome m6A writer METTL3 promotes chemo-and radioresistance in pancreatic cancer cells K Taketo, M Konno, A Asai, J Koseki, M Toratani, T Satoh, Y Doki, M Mori, ... International journal of oncology 52 (2), 621-629, 2018 | 344 | 2018 |
| Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non … Y Yamada, D Takahari, H Matsumoto, H Baba, M Nakamura, K Yoshida, ... The lancet oncology 14 (13), 1278-1286, 2013 | 274 | 2013 |
| Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic … K Tamura, I Okamoto, T Kashii, S Negoro, T Hirashima, S Kudoh, ... British journal of cancer 98 (5), 907-914, 2008 | 271 | 2008 |
| Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 … K Muro, N Boku, Y Shimada, A Tsuji, S Sameshima, H Baba, T Satoh, ... The lancet oncology 11 (9), 853-860, 2010 | 260 | 2010 |
| Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a … RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ... The Lancet 401 (10391), 1853-1865, 2023 | 231 | 2023 |
| Oncogene c-Myc promotes epitranscriptome m6A reader YTHDF1 expression in colorectal cancer Y Nishizawa, M Konno, A Asai, J Koseki, K Kawamoto, N Miyoshi, ... Oncotarget 9 (7), 7476, 2018 | 214 | 2018 |
| Differential constitutive activation of the epidermal growth factor receptor in non–small cell lung cancer cells bearing EGFR gene mutation and amplification T Okabe, I Okamoto, K Tamura, M Terashima, T Yoshida, T Satoh, ... Cancer research 67 (5), 2046-2053, 2007 | 214 | 2007 |
| Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START) W Koizumi, YH Kim, M Fujii, HK Kim, H Imamura, KH Lee, T Hara, ... Journal of cancer research and clinical oncology 140, 319-328, 2014 | 210 | 2014 |
| Adipose‐derived mesenchymal stem cells and regenerative medicine M Konno, A Hamabe, S Hasegawa, H Ogawa, T Fukusumi, S Nishikawa, ... Development, growth & differentiation 55 (3), 309-318, 2013 | 209 | 2013 |
| Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors T Satoh, I Okamoto, M Miyazaki, R Morinaga, A Tsuya, Y Hasegawa, ... Clinical Cancer Research 15 (11), 3872-3880, 2009 | 209 | 2009 |
| KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. CS Fuchs, T Doi, RWJ Jang, K Muro, T Satoh, M Machado, W Sun, ... Journal of Clinical Oncology 35 (15_suppl), 4003-4003, 2017 | 204 | 2017 |
